-

Autobahn Therapeutics to Present at the Morgan Stanley 21st Annual Global Healthcare Conference

SAN DIEGO--(BUSINESS WIRE)--Autobahn Therapeutics, a biotechnology company leveraging its brain-targeting chemistry platform, validated biology and biomarker-driven strategies to develop restorative treatments for people affected by central nervous system (CNS) disorders, today announced that Kevin Finney, President and Chief Executive Officer, will present a company overview at the Morgan Stanley 21st Annual Global Healthcare Conference in New York on Monday, September 11, 2023, at 12:55 p.m. ET.

About Autobahn Therapeutics 
Autobahn Therapeutics is a biotechnology company developing a portfolio of neuropsychiatric and neurodegenerative clinical candidates leveraging its brain-targeting chemistry platform. Autobahn aims to unlock new therapeutic opportunities through precision tuning of CNS exposure, pursuing validated clinical and biologic targets, and guiding development with biomarkers. The company’s pipeline is led by ABX-002, a thyroid hormone receptor beta agonist, being developed as a potential adjunctive treatment for people with major depressive disorder (MDD), including those who have had an inadequate response to their antidepressant. Autobahn Therapeutics is based in San Diego. For more information, visit www.autobahntx.com.

Contacts

Alex Straus, THRUST Strategic Communications
alex@thrustsc.com

Autobahn Therapeutics


Release Versions

Contacts

Alex Straus, THRUST Strategic Communications
alex@thrustsc.com

More News From Autobahn Therapeutics

Autobahn Therapeutics to Participate in Jefferies Global Healthcare Conference

SAN DIEGO--(BUSINESS WIRE)--Autobahn Therapeutics, a biotechnology company developing restorative treatments for people affected by neuropsychiatric and neuroimmunologic disorders, today announced that Kevin Finney, President and Chief Executive Officer, will participate in the Jefferies Global Healthcare Conference on Tuesday, June 3, 2025, in New York. About Autobahn Therapeutics Autobahn Therapeutics is a biotechnology company developing a portfolio of neuropsychiatric and neuroimmunologic c...

Autobahn Therapeutics Announces Presentation of ABX-002 Phase 1 Clinical Results at the 2025 ASCP Annual Meeting

SAN DIEGO--(BUSINESS WIRE)--Autobahn Therapeutics, a biotechnology company developing restorative treatments for people affected by neuropsychiatric and neuroimmunologic disorders, today announced the company will present the clinical results from its completed Phase 1 trial of ABX-002 at the 2025 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting, taking place May 27-30, 2025, in Scottsdale, AZ. ABX-002 is a highly potent, oral, thyroid hormone beta receptor (TRβ) selective...

Autobahn Therapeutics Announces Initiation of Phase 2 Trial of ABX-002 as an Adjunctive Treatment for Bipolar Depression

SAN DIEGO--(BUSINESS WIRE)--Autobahn Therapeutics, a biotechnology company developing restorative treatments for people affected by neuropsychiatric and neuroimmunologic disorders, today announced the initiation of a Phase 2 clinical trial evaluating ABX-002, its highly potent, oral, thyroid hormone beta receptor (TRβ) selective agonist, as an adjunctive treatment in adults with bipolar depression. The Phase 2 trial aims to establish biological and clinical proof-of-concept for ABX-002 in bipol...
Back to Newsroom